Do I have to take a GLP-1 forever? An honest answer, and a plan

Many people do take one long term, because the benefit lasts only while you take it. In trials, people who stopped semaglutide or tirzepatide regained much of their lost weight within a year, while people who kept going held on to their loss. A lower dose or a daily pill can work for some people. A physician can help you plan what's right for you.

Reviewed by Darshan Patel, MD, Obesity medicine physician, on 2026-11-12. Next review 2027-05-11.

Book my consultation Video consultations with an obesity medicine physician. Most major insurance accepted, plus convenient cash pay options.

The short answer

It's a fair question, and a smart one to ask before you start. You want to know what you're signing up for.

For most people, a GLP-1 medicine works while you take it. Obesity is a long-term condition, and the researchers who followed people after they stopped semaglutide said their findings confirm that. The FDA labels for Wegovy and Zepbound describe them as medicines to "reduce excess body weight and maintain weight reduction long term," together with a reduced-calorie diet and more physical activity.

That doesn't mean you've failed if you need one for years. When weight comes off, the body pushes back: hunger signals return and the body burns a little less energy. That's biology, not willpower. The medicine helps quiet that push while you take it.

What happens when people stop

Large trials, and a review of many studies, have looked at this directly.

• Semaglutide (the medicine in Wegovy). In the STEP 1 trial extension, people lost 17.3% of their body weight over 68 weeks. Then the medicine and the lifestyle program both stopped. A year later they had regained about two-thirds of what they'd lost, ending about 5.6% below where they started. Most of the gains in heart and metabolic health measures drifted back toward where they began, too.
• Tirzepatide (the medicine in Zepbound). In SURMOUNT-4, people lost an average of 20.9% over 36 weeks. Those switched to a placebo regained 14% of their body weight over the next year.
• Across many studies. A 2026 review of 37 studies found weight came back at about 0.4 kg (a little under a pound) a month on average after people stopped a weight medicine. That was faster than after diet-and-behavior programs, and heart and metabolic markers were projected to return to baseline within about a year and a half.

What happens when people keep going

• In STEP 4, people who stayed on semaglutide lost another 7.9% over the next 48 weeks, while people switched to placebo gained back 6.9%. Waist size, blood pressure and physical functioning also improved more for those who stayed on it.
• In SURMOUNT-4, people who stayed on tirzepatide lost another 5.5%. About 9 in 10 of them (89.5%) kept at least 80% of their earlier weight loss, compared with about 1 in 6 (16.6%) of people switched to placebo.

Long term doesn't have to mean the same forever

Your plan can change as your life and your body change. Here's what has been tested.

• A lower dose. In SURMOUNT-MAINTAIN, people who had lost weight on tirzepatide were split into three groups for a year. Over the full 112 weeks, those who stayed on their full dose ended 21.9% below their starting weight, those who stepped down to a lower dose ended 16.6% below, and those switched to placebo ended 9.9% below. The researchers called a lower dose a possible alternative to stopping, noting that each person's response may vary.
• A daily pill. In ATTAIN-MAINTAIN, people who had lost weight on tirzepatide or semaglutide injections switched to orforglipron, a once-daily GLP-1 pill now sold as Foundayo, or to placebo. A year later, the pill groups had kept about 75% to 79% of their weight loss, compared with about 38% to 49% on placebo. The trial didn't compare the pill with staying on injections.
• Exercise and muscle. Strength work and enough protein help you hold on to muscle while you lose, and exercise has trial support for keeping weight off after a medicine stops. See keeping muscle on a GLP-1 and how much protein you need.

Thinking about stopping? Read how to stop Wegovy or Zepbound without regaining before you do.

Care built for keeping it off

In everyday practice, only about a third to a half of people are still taking their GLP-1 a year later. Think of the medicine as a head start, not the whole plan. The habits you build while you're on it, and a clear plan for what comes next, matter just as much.

At Aayu Well, an obesity medicine physician sees you by video, a registered dietitian helps you build meals with enough protein, and your care team is a message away between visits. We prescribe GLP-1 medicines when they're right for you, and we plan from the start for keeping the weight off: when to stay on, when a lower dose or a different medicine makes sense, and what to do if life changes. If you've tried before and struggled, you weren't doing it wrong. You were doing it without the right support.

Most major insurance accepted, plus convenient cash pay options. Book my consultation

Good to know

• Plan any stop, pause or dose change with your prescriber rather than on your own.
• The trials in this guide studied the brand-name medicines along with diet and activity changes. Results vary from person to person.
• If you're planning a pregnancy, the Wegovy label advises stopping it at least 2 months beforehand, and the Zepbound label advises stopping when a pregnancy is recognized. Your physician will help you time it.

More physician-reviewed guides are in Learn, and our editorial policy explains how we choose sources and grade evidence.

Questions people ask

Can an Aayu Well physician help me decide whether to stay on my GLP-1?

Yes. That's one of the most common conversations we have. Your obesity medicine physician looks at how much you've lost, how you feel, your health numbers and your side effects, then talks through staying on, stepping down or changing medicine. A registered dietitian helps with the food side. Most major insurance accepted, plus convenient cash pay options.

Will I gain all the weight back if I stop?

Not always all of it, but most people regain a good share. In the STEP 1 trial extension, people regained about two-thirds of the weight they had lost on semaglutide in the year after stopping, and ended about 5.6% below where they started. Everyone is different, which is why it helps to plan any stop with your physician.

Can I stay on a lower dose to keep the weight off?

For some people, yes. In the SURMOUNT-MAINTAIN trial, people who stepped down to a lower dose of tirzepatide kept more of their loss than people who stopped, though less than people who stayed on their full dose. Your physician can help you decide whether stepping down makes sense for you.

Is it safe to take a GLP-1 for years?

The maintenance trials in this guide followed people for up to about two years. The most common side effects were stomach-related and mostly mild to moderate. Your physician will keep checking in with you about how the medicine is working and how you feel.

Why do so many people stop?

In everyday practice, only about a third to a half of people are still taking their GLP-1 a year later. Stomach side effects, a slower response than hoped, and changes in insurance coverage or cost are among the reasons. Many of these can be talked through with a physician before you decide.

Sources

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564
2. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425
3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48
4. Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318
5. Aronne LJ, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026;32(7):2679-2687
6. West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304
7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. Obesity Pillars. 2025;15:100181
8. Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine. 2024;69:102475
9. Marchetti M, et al. Weight regain after discontinuation of GLP-1 and GIP/GLP-1 receptor agonists: a systematic review. Metabolites. 2026;16(10):757
10. Shah E, et al. Clinical management of weight regain and cardiometabolic consequences after discontinuation of GLP-1 receptor agonists. Diabetes Obes Metab. 2026;28(6):4546-4558
11. Wegovy (semaglutide) prescribing information, DailyMed, revised 6/2026
12. Zepbound (tirzepatide) prescribing information, DailyMed, revised 8/2026
13. Foundayo (orforglipron) prescribing information, DailyMed